High levels of lipoprotein(a) (Lp(a)) are a genetically determined independent risk factor for cardiovascular disease that cannot be modified through lifestyle changes. Now, a study in Nature reports ...

Icosapent ethyl (Vascepa; Amarin) remains effective at reducing cardiovascular events in patients with elevated triglycerides but relatively well-controlled LDL cholesterol on a statin irrespective of ...

Experts discuss the integration of Lp(a) testing into cardiovascular risk assessment, and refining preventive strategies and statin use in specific groups. This is a video synopsis/summary of an ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

Please provide your email address to receive an email when new articles are posted on . Lipoprotein(a) should be measured in all people at least once. “Evaluation and management of Lp(a) is actionable ...

Lipoprotein(a), the low-density lipoprotein (LDL)-like particle that is currently the focus of so much enthusiastic research, is significantly more atherogenic than LDL cholesterol, according to a ...

Whether to measure Lp(a), a lipoprotein associated with increased cardiovascular risk, and how to use that information in risk assessment is a hot topic in cardiovascular medicine. The American Heart ...

Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its ...

Elevated lipoprotein(a) levels can slowly block the arteries, increasing the likelihood of cardiovascular disease. Since no treatment is currently available for this condition, it is essential to ...